Alterity Therapeutics Files 6-K, Incorporates Activities Report
Ticker: PRNAF · Form: 6-K · Filed: Oct 31, 2025 · CIK: 1131343
| Field | Detail |
|---|---|
| Company | Alterity Therapeutics Ltd (PRNAF) |
| Form Type | 6-K |
| Filed Date | Oct 31, 2025 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: reporting, sec-filing, foreign-private-issuer
TL;DR
ALTERITY THERAPEUTICS LTD files 6-K, includes Appendix 4C activities report, relevant for S-8 and F-3 filings.
AI Summary
Alterity Therapeutics Limited filed a Form 6-K on October 30, 2025, incorporating by reference its Quarterly Activities/Appendix 4C report. This filing is related to its ongoing registration statements on Form S-8 and Form F-3, indicating continued reporting obligations for its securities.
Why It Matters
This filing serves as an update for investors regarding Alterity Therapeutics' activities and financial status, as required for companies with securities registered in the US.
Risk Assessment
Risk Level: low — This is a routine filing (6-K) that incorporates other reports, not announcing new material events or financial distress.
Key Players & Entities
- Alterity Therapeutics Limited (company) — Registrant
- October 30, 2025 (date) — Filing date
- Form 6-K (document) — Filing type
- Appendix 4C (document) — Incorporated report
- Form S-8 (document) — Registration statement
- Form F-3 (document) — Registration statement
FAQ
What is the primary purpose of this Form 6-K filing?
The primary purpose is to report information required by the Securities and Exchange Commission (SEC) for foreign private issuers, specifically incorporating by reference the Quarterly Activities/Appendix 4C report.
Which registration statements is this 6-K filing being incorporated into?
This Form 6-K is being incorporated by reference into Alterity Therapeutics' Registration Statements on Form S-8 (Files No. 333-251073, 333-248980, and 333-228671) and Form F-3 (Files No. 333-274816, 333-251647, 333-231417, and 333-250076).
What is the filing date of this Form 6-K?
The filing date of this Form 6-K is October 30, 2025.
What specific report is being submitted as an exhibit with this 6-K?
The exhibit submitted with this 6-K is titled '99.1 Quarterly Activities/Appendix 4C'.
What is the principal executive office address of Alterity Therapeutics Limited?
The principal executive office address is Level 14, 350 Collins Street, Melbourne, Victoria 3000, Australia.
Filing Stats: 191 words · 1 min read · ~1 pages · Grade level 12.2 · Accepted 2025-10-31 07:12:43
Filing Documents
- ea0263355-6k_alterity.htm (6-K) — 13KB
- ea026335501ex99-1_alterity.htm (EX-99.1) — 116KB
- ex99-1_001.jpg (GRAPHIC) — 5KB
- 0001213900-25-104376.txt ( ) — 138KB
From the Filing
OF FOREIGN PRIVATE ISSUER SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-163 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October 30, 2025 Alterity Therapeutics Limited (Name of Registrant) Level 14, 350 Collins Street, Melbourne, Victoria 3000 Australia (Address of Principal Executive Office) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F Form 40-F This Form 6-K is being incorporated by reference into our Registration Statement on Form S-8 (Files No. 333-251073 , 333-248980 and 333-228671 ) and our Registration Statements on Form F-3 (Files No. 333-274816 , 333-251647 , 333-231417 and 333-250076 ) ALTERITY THERAPEUTICS LIMITED (a development stage enterprise) The following exhibits are submitted: 99.1 Quarterly Activities/Appendix 4C Cash Flow Report 1 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Alterity Therapeutics Limited By: /s/ Geoffrey P. Kempler Geoffrey P. Kempler Chairman Date: October 31, 2025 2